A Long Neglected World Malaria Map: \u3ci\u3ePlasmodium vivax\u3c/i\u3e Endemicity in 2010 by Gething, Peter W. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2012
A Long Neglected World Malaria Map:




Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
Catherine L. Moyes
University of Oxford, catherine.moyes@bdi.ox.ac.uk
David L. Smith
Johns Hopkins Bloomberg School of Public Health
Katherine E. Battle
University of Oxford
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Gething, Peter W.; Elyazar, Iqbal R.F.; Moyes, Catherine L.; Smith, David L.; Battle, Katherine E.; Guerra, Carlos A.; Patil, Anand P.;
Tatem, Andrew J.; Howes, Rosalind E.; Myers, Monica F.; George, Dylan B.; Horby, Peter; Wertheim, Heiman F.L.; Price, Ric N.;
Mueller, Ivo; Baird, J. Kevin; and Hay, Simon I., "A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010"
(2012). Public Health Resources. 349.
http://digitalcommons.unl.edu/publichealthresources/349
Authors
Peter W. Gething, Iqbal R.F. Elyazar, Catherine L. Moyes, David L. Smith, Katherine E. Battle, Carlos A.
Guerra, Anand P. Patil, Andrew J. Tatem, Rosalind E. Howes, Monica F. Myers, Dylan B. George, Peter Horby,
Heiman F.L. Wertheim, Ric N. Price, Ivo Mueller, J. Kevin Baird, and Simon I. Hay
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/
publichealthresources/349
A Long Neglected World Malaria Map: Plasmodium vivax
Endemicity in 2010
Peter W. Gething1*, Iqbal R. F. Elyazar2, Catherine L. Moyes1, David L. Smith3,4, Katherine E. Battle1,
Carlos A. Guerra1, Anand P. Patil1, Andrew J. Tatem4,5, Rosalind E. Howes1, Monica F. Myers1,
Dylan B. George4, Peter Horby6,7, Heiman F. L. Wertheim6,7, Ric N. Price7,8,9, Ivo Müeller10, J.
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Abstract
Background: Current understanding of the spatial epidemiology and geographical distribution of Plasmodium vivax is far
less developed than that for P. falciparum, representing a barrier to rational strategies for control and elimination. Here we
present the first systematic effort to map the global endemicity of this hitherto neglected parasite.
Methodology and Findings: We first updated to the year 2010 our earlier estimate of the geographical limits of P. vivax
transmission. Within areas of stable transmission, an assembly of 9,970 geopositioned P. vivax parasite rate (PvPR) surveys
collected from 1985 to 2010 were used with a spatiotemporal Bayesian model-based geostatistical approach to estimate
endemicity age-standardised to the 1–99 year age range (PvPR1–99) within every 565 km resolution grid square. The model
incorporated data on Duffy negative phenotype frequency to suppress endemicity predictions, particularly in Africa.
Endemicity was predicted within a relatively narrow range throughout the endemic world, with the point estimate rarely
exceeding 7% PvPR1–99. The Americas contributed 22% of the global area at risk of P. vivax transmission, but high endemic
areas were generally sparsely populated and the region contributed only 6% of the 2.5 billion people at risk (PAR) globally.
In Africa, Duffy negativity meant stable transmission was constrained to Madagascar and parts of the Horn, contributing
3.5% of global PAR. Central Asia was home to 82% of global PAR with important high endemic areas coinciding with dense
populations particularly in India and Myanmar. South East Asia contained areas of the highest endemicity in Indonesia and
Papua New Guinea and contributed 9% of global PAR.
Conclusions and Significance: This detailed depiction of spatially varying endemicity is intended to contribute to a much-
needed paradigm shift towards geographically stratified and evidence-based planning for P. vivax control and elimination.
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Introduction
The international agenda shaping malaria control financing,
research, and implementation is increasingly defined around the
goal of regional elimination [1–6]. This ambition ostensibly
extends to all human malarias, but whilst recent years have seen a
surge in research attention for Plasmodium falciparum, the knowl-
edge-base for the other major human malaria, Plasmodium vivax, is
far less developed in almost every aspect [7–11]. During 2006–
2009 just 3.1% of expenditures on malaria research and
development were committed to P. vivax [12]. The notion that
control approaches developed primarily for P. falciparum in
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holoendemic Africa can be transferred successfully to P. vivax is,
however, increasingly acknowledged as inadequate [13–17].
Previous eradication campaigns have demonstrated that P. vivax
frequently remains entrenched long after P. falciparum has been
eliminated [18]. The prominence of P. vivax on the global health
agenda has risen further as evidence accumulates of its capacity in
some settings to cause severe disease and death [19–25], and of the
very large numbers of people living at risk [26].
Amongst the many information gaps preventing rational
strategies for P. vivax control and elimination, the absence of
robust geographical assessments of risk has been identified as
particularly conspicuous [9,27]. The endemic level of the disease
determines its burden on children, adults, and pregnant women;
the likely impact of different control measures; and the relative
difficulty of elimination goals. Despite the conspicuous impor-
tance of these issues, there has been no systematic global
assessment of endemicity. The Malaria Atlas Project was initiated
in 2005 with an initial focus on P. falciparum that has led to global
maps [28–30] for this parasite being integrated into policy
planning at regional to international levels [4,31–36]. Here we
present the outcome of an equivalent project to generate a
comprehensive evidence-base on P. vivax infections worldwide,
and to generate global risk maps for this hitherto neglected
disease. We build on earlier work [26] defining the global range
of the disease and broad classifications of populations at risk to
now assess the levels of endemicity under which these several
billion people live. This detailed depiction of geographically
varying risk is intended to contribute to a much-needed paradigm
shift towards geographically stratified and evidence-based plan-
ning for P. vivax control and elimination.
Numerous biological and epidemiological characteristics of P.
vivax present unique challenges to defining and mapping metrics of
risk. Unlike P. falciparum, infections include a dormant hypnozoite
liver stage that can cause clinical relapse episodes [37,38]. These
periodic events manifest as a blood-stage infection clinically
indistinguishable from a primary infection and constitute a
substantial, but geographically varying, proportion of total patent
infection prevalence and disease burden within different popula-
tions [37,39–41]. The parasitemia of P. vivax typically occurs at
much lower densities compared to those of falciparum malaria,
and successful detection by any given means of survey is much less
likely. Another major driver of the global P. vivax landscape is the
influence of the Duffy negativity phenotype [42]. This inherited
blood condition confers a high degree of protection against P. vivax
infection and is present at very high frequencies in the majority of
African populations, although is rare elsewhere [43]. These
factors, amongst others, mean that the methodological framework
for mapping P. vivax endemicity, and the interpretation of the
resulting maps, are distinct from those already established for P.
falciparum [28,29]. The effort described here strives to accommo-
date these important distinctions in developing a global distribu-
tion of endemic vivax malaria.
Methods
The modelling framework is displayed schematically in
Figure 1. In brief, this involved (i) updating of the geographical
limits of stable P. vivax transmission based on routine reporting
data and biological masks; (ii) assembly of all available P. vivax
parasite rate data globally; (iii) development of a Bayesian model-
based geostatistical model to map P. vivax endemicity within the
limits of stable transmission; and (iv) a model validation
procedure. Details on each of these stages are provided below
with more extensive descriptions included as Protocols S1, S2, S3,
and S4.
Updating Estimates of the Geographical Limits of
Endemic Plasmodium vivax in 2010
The first effort to systematically estimate the global extent of P.
vivax transmission and define populations at risk was completed in
2009 [26]. As a first step in the current study, we have updated this
work with a new round of data collection for the year 2010. The
updated data assemblies and methods are described in full in
Protocol S1. In brief, this work first involved the identification of
95 countries as endemic for P. vivax in 2010. From these, P. vivax
annual parasite incidence (PvAPI) routine case reports were
assembled from 17,893 administrative units [44]. These PvAPI
and other medical intelligence data were combined with remote
sensing surfaces and biological models [45] that identified areas
where extreme aridity or temperature regimes would limit or
preclude transmission (see Protocol S1). These components were
combined to classify the world into areas likely to experience zero,
unstable (PvAPI ,0.1% per annum), or stable (PvAPI $0.1% per
annum) P. vivax transmission. Despite the very high population
frequencies of Duffy negativity across much of Africa, the presence
of autochthonous transmission of P. vivax has been confirmed by a
systematic literature review for 42 African countries [26]. We
therefore treated Africa in the same way as elsewhere in this initial
stage: regions were deemed to have stable P. vivax transmission
unless the biological mask layers or PvAPI data suggested
otherwise.
Author Summary
Plasmodium vivax is one of five parasites causing malaria in
humans. Whilst it is found across a larger swathe of the
globe and potentially affects a larger number of people
than its more notorious cousin, Plasmodium falciparum, it
receives a tiny fraction of the research attention and
financing: around 3%. This neglect, coupled with the
inherently more complex nature of vivax biology, means
important knowledge gaps remain that limit our current
ability to control the disease effectively. This patchy
knowledge is becoming recognised as a cause for concern,
in particular as the global community embraces the
challenge of malaria elimination which, by definition,
includes P. vivax and the other less common Plasmodium
species as well as P. falciparum. Particularly conspicuous is
the absence of an evidence-based map describing the
intensity of P. vivax endemicity in different parts of the
world. Such maps have proved important for other
infectious diseases in supporting international policy
formulation and regional disease control planning, imple-
mentation, and monitoring. In this study we present the
first systematic effort to map the global endemicity of P.
vivax. We assembled nearly 10,000 surveys worldwide in
which communities had been tested for the prevalence of
P. vivax infections. Using a spatial statistical model and
additional data on environmental characteristics and Duffy
negativity, a blood disorder that protects against P. vivax,
we estimated the level of infection prevalence in every
565 km grid square across areas at risk. The resulting
maps provide new insight into the geographical patterns
of the disease, highlighting areas of the highest endemic-
ity in South East Asia and small pockets of Amazonia, with
very low endemic setting predominating in Africa. This
new level of detailed mapping can contribute to a wider
shift in our understanding of the spatial epidemiology of
this important parasite.
Global Plasmodium vivax Endemicity in 2010
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Creating a Database of Georeferenced PvPR Data
As with P. falciparum, the most globally ubiquitous and
consistently measured metric of P. vivax endemicity is the parasite
rate (PvPR), defined as the proportion of randomly sampled
individuals in a surveyed population with patent parasitemia in
their peripheral blood as detected via, generally, microscopy or
rapid diagnostic test (RDT). Whilst RDTs can provide lower
sensitivity and specificity than conventional blood smear micros-
copy, and neither technique provides accuracy comparable to
molecular diagnostics (such as polymerase chain reaction, PCR),
the inclusion of both microscopically and RDT confirmed parasite
rate data was considered important to maximise data availability
and coverage across the endemic world.
To map endemicity within the boundaries of stable transmis-
sion, we first carried out an exhaustive search and assembly of
georeferenced PvPR survey data from formal and informal
literature sources and direct communications with data generating
organisations [46]. Full details of the data search strategy,
abstraction and inclusion criteria, geopositioning and fidelity
checking procedure are included in Protocol S2. The final
database, completed on 25th November 2011, consisted of 9,970
quality-checked and spatiotemporally unique data points, span-
ning the period 1985–2010. Figure 2A maps the spatial
distribution of these data and further summaries by survey origin,
georeferencing source, time period, age group, sample size, and
type of diagnostic used are provided in Protocol S2.
Modelling Plasmodium vivax Endemicity within Regions
of Stable Transmission
We adopt model-based geostatistics (MBG) [47,48] as a robust
and flexible modelling framework for generating continuous
surfaces of malaria endemicity based on retrospectively assembled
parasite rate survey data [28,29,49]. MBG models are a special
class of generalised linear mixed models, with endemicity values at
each target pixel predicted as a function of a geographically-
varying mean and a weighted average of proximal data points.
The mean can be defined as a multivariate function of
environmental correlates of disease risk. A covariance function is
used to characterise the spatial or space-time heterogeneity in the
observed data, which in turn is used to define appropriate weights
assigned to each data point when predicting at each pixel. This
framework allows the uncertainty in predicted endemicity values
to vary between pixels, depending on the observed variation,
density and sample size of surveys in different locations and the
predictive utility of the covariate suite. Parts of the map where
survey data are dense, recent, and relatively homogenous will be
predicted with least uncertainty, whilst regions with sparse or
mainly old surveys, or where measured parasite rates are
extremely variable, will have greater uncertainty. When MBG
models are fitted using Bayesian inference and a Markov chain
Monte Carlo (MCMC) algorithm, uncertainty in the final
predictions as well as all model parameters can be represented
in the form of predictive posterior distributions [50].
Figure 1. Schematic overview of the mapping procedures and methods for Plasmodium vivax endemicity. Blue boxes describe input
data. Orange boxes denote models and experimental procedures; green boxes indicate output data (dashed lines represent intermediate outputs
and solid lines final outputs). U/R = urban/rural; UNPP = United Nations Population Prospects. Labels S1-4 denote supplementrary information in
Protocols S1, S2, S3, and S4.
doi:10.1371/journal.pntd.0001814.g001
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We developed for this study a modified version of the MBG
framework used previously to model P. falciparum endemicity
[28,29], with some core aspects of the model structure remaining
unchanged and others altered to capture unique aspects of P. vivax
biology and epidemiology. The model is presented in full in
Protocol S3. As in earlier work [28,29,49], we adopt a space-time
approach to allow surveys from a wide time period to inform
predictions of contemporary risk. This includes the use of a
spatiotemporal covariance function which is parameterised to
downweight older data appropriately. We also retain a seasonal
component in the covariance function, although we note that
seasonality in transmission is often only weakly represented in
PvPR in part because of the confounding effect of relapses
occurring outside peak transmission seasons [51]. A minimal set of
covariates were included to inform prediction of the mean
function, based on a priori expectations of the major environmental
factors modulating endemicity. These were (i) an indicator variable
defining areas as urban or rural based on the Global Rural Urban
Mapping Project (GRUMP) urban extent product [52,53]; (ii) a
long-term average vegetation index product as an indicator of
overall moisture availability for vector oviposition and survival
[54,55]; and (iii) a P. vivax specific index of temperature suitability
derived from the same model used to delineate suitable areas on
the basis of vector survival and sporogony [45].
Age Standardisation
Our assembly of PvPR surveys was collected across a variety of
age ranges and, since P. vivax infection status can vary
systematically in different age groups within a defined community,
it was necessary to standardise for this source of variability to allow
all surveys to be used in the same model. We adopted the same
model form as has been described [56] and used previously for P.
falciparum [28,29], whereby population infection prevalence is
expected to rise rapidly in early infancy and plateau during
childhood before declining in early adolescence and adulthood.
The timing and relative magnitude of these age profile features are
Figure 2. The spatial distribution of Plasmodium vivax malaria endemicity in 2010. Panel A shows the 2010 spatial limits of P. vivax malaria
risk defined by PvAPI with further medical intelligence, temperature and aridity masks. Areas were defined as stable (dark grey areas, where PvAPI
$0.1 per 1,000 pa), unstable (medium grey areas, where PvAPI ,0.1 per 1,000 pa) or no risk (light grey, where PvAPI = 0 per 1,000 pa). The
community surveys of P. vivax prevalence conducted between January 1985 and June 2010 are plotted. The survey data are presented as a
continuum of light green to red (see map legend), with zero-valued surveys shown in white. Panel B shows the MBG point estimates of the annual
mean PvPR1–99 for 2010 within the spatial limits of stable P. vivax malaria transmission, displayed on the same colour scale. Areas within the stable
limits in (A) that were predicted with high certainty (.0.9) to have a PvPR1–99 less than 1% were classed as unstable. Areas in which Duffy negativity
gene frequency is predicted to exceed 90% [43] are shown in hatching for additional context.
doi:10.1371/journal.pntd.0001814.g002
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likely distinct between the two parasites in different endemic
settings [51,57], and so the model was parameterised using an
assembly of 67 finely age-stratified PvPR surveys (Protocol S2),
with estimation carried out in a Bayesian model using MCMC.
The parameterised model was then used to convert all observed
survey prevalences to a standardised age-independent value for use
in modelling, and then further allowed the output prevalence
predictions to be generated for any arbitrary age range. We chose
to generate maps of all-age infection prevalence, defined as
individuals of age one to 99 years (thus PvPR1–99). We excluded
infection in those less than one year of age from the standardisa-
tion because of the confounding effect of maternal antibodies, and
because parasite rate surveys very rarely sample young infants. We
deviated from the two-to-ten age range used for mapping P.
falciparum [28,29] because the relatively lower prevalences has
meant that surveys are far more commonly carried out across all
age ranges.
Incorporating Duffy Negativity
Since Duffy negative individuals are largely refractory to P. vivax
infection [58], high population frequencies of this phenotype have
a dramatic suppressing effect on endemicity, even where
conditions are otherwise well suited for transmission [26]. The
predominance of Duffy negativity in Africa has led to a historical
perception that P. vivax is absent from much of the continent, and a
dearth of surveys or routine diagnoses testing for the parasite have
served to entrench this mantra [59]. However, evidence exists of
autochthonous P. vivax transmission across the continent [26], and
therefore we did not preclude any areas at risk a priori. Instead, we
used a recent map of estimated Duffy negativity phenotypic
frequency [43] and incorporated the potential influence of this
blood group directly in the MBG modelling framework. The
mapped Duffy-negative population fraction at each location was
excluded from the denominator in PvPR survey data, such that
any P. vivax positive individuals were considered to have arisen
from the Duffy positive population subset. Thus in a location with
90% Duffy negativity, five positive individuals in a survey of 100
would give an assumed prevalence of 50% amongst Duffy
positives. Correspondingly, prediction of PvPR was then restricted
to the Duffy positive proportion at each pixel, with the final
prevalence estimate re-converted to relate to the total population.
This approach has two key advantages. First, predicted PvPR at
each location could never exceed the Duffy positive proportion,
therefore ensuring biological consistency between the P. vivax and
Duffy negativity maps. Second, where PvPR survey data were
sparse across much of Africa, the predictions could effectively
borrow strength from the Duffy negativity map because predic-
tions of PvPR were restricted to a much narrower range of possible
values.
Model Implementation and Map Generation
The P. vivax endemic world was divided into four contiguous
regions with broadly distinct biogeographical, entomological and
epidemiological characteristics: the Americas and Africa formed
separate regions, whilst Asia was subdivided into Central and
South East sub-regions with a boundary at the Thailand-Malaysia
border (see Protocol S2). This regionalisation was implemented in
part to retain computational feasibility given the large number of
data points, but also to allow model parameterisations to vary and
better capture regional endemicity characteristics. Within each
region, a separate MBG model was fitted using a bespoke MCMC
algorithm [60] to generate predictions of PvPR1–99 for every
565 km pixel within the limits of stable transmission. The
prediction year was set to 2010 and model outputs represent an
annualised average across the 12 months of that year. Model
output consisted of a predicted posterior distribution of PvPR1–99
for every pixel. A continuous endemicity map was generated using
the mean of each posterior distribution as a point estimate. The
uncertainty associated with predictions was summarised by maps
showing the ratio of the posterior distribution inter-quartile range
(IQR) to its mean. The IQR is a simple measure of the precision
with which each PvPR value was predicted, and standardisation by
the mean produced an uncertainty index less affected by
underlying prevalence levels and more illustrative of relative
model performance driven by data densities in different locations.
This index was then also weighted by the underlying population
density to produce a second map indicative of those areas where
uncertainty is likely to be most operationally important.
Refining Limits Definition and Population at Risk
Estimates
In some regions within the estimated limits of stable transmis-
sion, PvPR1–99 was predicted to be extremely low, either because
of a dense abundance of survey data reporting zero infections or,
in Africa, because of very high coincident Duffy negativity
phenotype frequencies. Such areas are not appropriately described
as being at risk of stable transmission and so we defined a decision
rule whereby pixels predicted with high certainty (probability
.0.9) of being less than 1% PvPR1–99 were assigned to the
unstable class, thereby modifying the original transmission limits.
These augmented mapped limits were combined with a 2010
population surface derived from the GRUMP beta version [52,53]
to estimate the number of people living at unstable or stable risk
within each country and region. The fraction of the population
estimated to be Duffy negative [43] within each pixel was
considered at no risk and therefore excluded from these totals.
Model Validation
A model validation procedure was implemented whereby 10%
of the survey points in each model region were selected using a
spatially declustered random sampling procedure. These subsets
were held out and the model re-fitted in full using the remaining
90%. Model predictions were then compared to the hold-out data
points and a number of different aspects of model performance
were assessed using validation statistics described previously
[28,29]. The validation procedure is detailed in full in Protocol S4.
Results
Model Validation
Full validation results are presented in Protocol S4. In brief,
examination of the mean error in the generation of the P. vivax
malaria endemicity point-estimate surface revealed minimal
overall bias in predicted PvPR with a global mean error of
20.41 (Americas 21.38, Africa 0.03, Central Asia 20.43, South
East Asia 20.43), with values in units of PvPR on a percentage
scale (see Protocol S4). The global value thus represents an overall
tendency to underestimate prevalence by just under half of one
percent. The mean absolute error, which measures the average
magnitude of prediction errors, was 2.48 (Americas 5.05, Africa
0.53, Central Asia 1.52, South East Asia 3.37), again in units of
PvPR (see Protocol S4).
Global Plasmodium vivax Endemicity and Populations at
Risk in 2010
The limits of stable and unstable P. vivax transmission, as defined
using PvAPI, biological exclusion masks and medical intelligence
Global Plasmodium vivax Endemicity in 2010
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data are shown in Figure 2A. The continuous surface of P. vivax
endemicity predicted within those limits is shown in Figure 2B.
The uncertainty map (posterior IQR:mean ratio) is shown in
Figure 3A and the population-weighted version in Figure 3B.
We estimate that P. vivax was endemic across some 44 million
square kilometres, approximately a third of the Earth’s land
surface. Around half of this area was located in Africa (51%) and a
quarter each in the Americas (22%) and Asia (27%) (Table 1).
However, the uneven distribution of global populations, coupled
with the protective influence of Duffy negativity in Africa, meant
that the distribution of populations at risk was very different. An
estimated 2.48 billion people lived at any risk of P. vivax in 2010
(Table 1), of which a large majority lived in Central Asia (82%)
with much smaller fractions in South East Asia (9%), the Americas
(6%), and Africa (3%). Of these, 1.52 billion lived in areas of
unstable transmission where risk is very low and case incidence is
unlikely to exceed one per 10,000 per annum. The remaining 964
million people at risk lived in areas of stable transmission,
representing a wide diversity of endemic levels. The global
distribution of populations in each risk class was similar to the total
at risk, such that over 80% of people in both classes lived in
Central Asia (Table 1).
Plasmodium vivax Endemicity in the Americas
Areas endemic for P. vivax in the Americas extended to some 9.5
million square kilometres, of which the largest proportion was in
the Amazonian region of Brazil (Figure 2B). Interestingly, only a
relatively small fraction of these areas (15%) experienced unstable
rather than stable transmission, suggesting a polarisation between
areas at stable risk and those where the disease is absent altogether
(Table 1). The regions of highest endemicity were found in
Amazonia and in Central America – primarily Nicaragua and
Honduras – with predicted mean PvPR1–99 exceeding 7% in all
three locations. An important feature of P. vivax throughout the
Americas is that its distribution is approximately inverse to that of
the population. This is particularly true of the two most populous
endemic countries of the region, Brazil and Mexico, and it means
that, whilst the Americas contributed 53% of the land area
experiencing stable transmission worldwide, they housed only 5%
of the global population at that level of risk.
Figure 3. Uncertainty associated with predictions of Plasmodium vivax endemicity. Panel A shows the ratio of the posterior inter-quartile
range to the posterior mean prediction at each pixel. Large values indicate greater uncertainty: the model predicts a relatively wide range of PvPR1–99
as being equally plausible given the surrounding data. Conversely, smaller values indicate a tighter range of values have been predicted and, thus, a
higher degree of certainty in the prediction. Panel B shows the same index multiplied by the underlying population density and rescaled to 0–1 to
correspond to Panel A. Higher values indicate areas with high uncertainty and large populations.
doi:10.1371/journal.pntd.0001814.g003
Global Plasmodium vivax Endemicity in 2010
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Uncertainty in predicted PvPR1–99 was relatively high through-
out much of the Americas (Figure 3B). This reflects the
heterogeneous landscape of endemicity coupled with the generally
scarce availability of parasite rate surveys in the region (see
Figure 2A). However, when this uncertainty is weighted by the
underlying population density (Figure 3B), its significance on a
global scale is placed in context: because most areas at stable risk
are sparsely populated, the population-weighted uncertainty was
very low compared to parts of Africa and much of Asia.
Plasmodium vivax Endemicity in Africa, Yemen and Saudi
Arabia (Africa+)
Our decision to assume stable transmission of P. vivax in Africa
unless robust PvAPI or biological mask data confirmed otherwise
meant that much of the continent south of the Sahara was initially
classified as being at stable risk (Figure 2A). However, by
implementing the MBG predictions of PvPR1–99 throughout this
range and reclassifying a posteriori those areas likely to fall below an
endemicity threshold of 1% PvPR1–99, the majority of stable risk
areas were downgraded to unstable (Figure 2B). Thus, in the final
maps, 92% of endemic Africa was at unstable risk, with the
majority of Madagascar and Ethiopia, and parts of South Sudan
and Somalia making up most of the remaining area at stable risk.
Even in these areas, endemicity was uniformly low, with predicted
endemicity values rarely exceeding a point estimate of 2% PvPR1–
99. We augmented the final map with an additional overlay mask
delineating areas where Duffy negativity phenotype prevalence has
been predicted to exceed 90% (Figure 2B). The influence of this
blood group on the estimated populations at risk is profound: of
the 840 million Africans living in areas within which transmission
is predicted to occur, only 86 million were considered at risk,
contributing just 3% to the global total (Table 1).
Uncertainty in predicted PvPR1–99 followed a similar pattern to
the magnitude of the predictions themselves (Figure 3B). Certainty
around the very low predicted endemicity values covering most of
the continent was extremely high – reflecting the increased precision
gained by incorporating the Duffy negativity information that
compensated for the paucity of P. vivax parasite rate surveys on the
continent. The pockets of higher endemicity in Madagascar and
northern East Africa were predicted with far less certainty. In the
population-weighted uncertainty map (Figure 3B), the lower
population densities of Madagascar reduced the index on that island
whereas the densely populated Ethiopian highlands remained high.
Plasmodium vivax Endemicity in Central and South East
Asia
Large swathes of high endemicity, very large population
densities and a negligible presence of Duffy negativity combine
to make the central and south-eastern regions of Asia by far the
most globally significant for P. vivax. We estimate that India alone
contributed nearly half (46%) of the global population at risk, and
two thirds (67%) of those at stable risk. China is another major
contributor with 19% of the global populations at risk, primarily in
unstable transmission regions, whilst Indonesia and Pakistan
together contributed a further 12%. Within regions of stable
transmission, endemicity is predicted to be extremely heteroge-
neous (Figure 2B). Areas where the point estimate of PvPR1–99
exceeded 7% were found in small pockets of India, Myanmar,
Indonesia, and the Solomon Islands, with the largest such region
located in Papua New Guinea.
The uncertainty map (Figure 3A) reveals how the most precise
predictions were associated with areas of uniformly low endemicity
and abundant surveys, such as Afghanistan and parts of Sumatra
and Kalimantan in Indonesia. Conversely, areas with higher or
more heterogeneous endemicity, such as throughout the island of
New Guinea, were the most uncertain. The population-weighted
uncertainty map (Figure 3B) differs substantively, indicating how
the populous areas of Indonesia, for example, were relatively
precisely predicted whereas India, China, and the Philippines had
the largest per-capita uncertainty.
Discussion
The status of P. vivax as a major public health threat affecting
the world’s most populous regions is becoming increasingly well
documented. The mantra of vivax malaria being a very rarely
threatening and relatively benign disease [7,10] has been
challenged with evidence suggesting that it can contribute a
significant proportion of severe malaria disease and death
attributable to malaria in some settings [61]. Some reports have
pointed especially to very young children being a major source of
morbidity [20,62] and some hospital-based studies have reported
comparable mortality rates between patients classified with severe
P. vivax and severe P. falciparum [21,24,63]. The recognition of a
lethal threat by this parasite comes with evidence of failing
chemotherapeutics against the acute attack [64] and overdue
acknowledgement of the practical inadequacy of the only available
therapy against relapse [65]. As the international community
defines increasingly ambitious targets to minimise malaria illness
and death [66–68], and to progressively eliminate the disease from
endemic areas [1–6], further sustained neglect of P. vivax becomes
increasingly untenable.
Here we have presented the first systematic attempt to map the
global distribution of P. vivax endemicity using a defined evidence
base, transparent methodologies, and with measured uncertainty.
These new maps aim to contribute to a more rational international
appraisal of the importance of P. vivax in the broad context of
Table 1. Area and populations at risk of Plasmodium vivax malaria in 2010.
Region Area (million km
2) Population (millions)
Unstable Stable Any risk Unstable Stable Any risk
America 1.38 8.08 9.46 87.66 49.79 137.45
Africa+ 20.60 1.86 22.46 48.72 37.66 86.38
C Asia 5.60 3.63 9.24 1,236.92 812.55 2,049.47
SE Asia 0.96 1.78 2.74 150.17 64.90 215.07
World 28.55 15.35 43.90 1,523.47 964.90 2,488.37
Risk is stratified into unstable risk (PvAPI,0.1 per 1,000 people pa) and stable risk (PvAPI$0.1 per 1,000 people pa).
doi:10.1371/journal.pntd.0001814.t001
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malaria control and elimination policies, as well as providing a
practical tool to support control planning at national and sub-
national levels.
Interpreting P. vivax Endemicity in 2010
In 2010, areas endemic for P. vivax covered a huge geographical
range spanning three major continental zones and extending into
temperate climates. In the Americas, whilst important pockets of
high endemicity are present, the majority of areas of stable
transmission coincide with lower population densities, diminishing
the contribution of this continent to global populations at risk. In
Africa the protection conferred by Duffy negativity to most of the
population means the large swathes of the continent in which
transmission may occur contain only small populations at
biological risk. Thus it is primarily in Asia where very large
populations coincide with extensive high endemic regions, and as a
result nine out of every ten people at risk of P. vivax globally live on
that continent.
A number of important contrasts arise when comparing this
map with the equivalent 2010 iteration for P. falciparum [28].
Perhaps most obvious are the lower levels of observed endemicity
at which P. vivax tends to exist within populations experiencing
stable transmission. We used a cartographic scale between 0% and
7% to differentiate global variation in P. vivax endemicity, although
point estimates exceeded that upper threshold in localised areas.
For P. falciparum the equivalent scale spanned 0% to 70% [28],
suggesting an approximate order-of-magnitude difference in
prevalence of patent parasitemia. In part, this difference reflects
the decision to standardise our predictions across the 1–99 age
range, and values would have been higher if we had opted for the
peak 2–10 age range used for P. falciparum. This difference might
be accentuated by the likely more rapid acquisition of immunity to
P. vivax than P. falciparum in the most highly endemic areas [57]. A
number of other biological and epidemiological differences
between the two species also mean these lower apparent levels
of endemicity must be interpreted differently. One factor is the
lower sensitivities of microscopy and RDT diagnoses for a given
level of P. vivax infection prevalence, because infections tend to be
associated with much lower parasite densities which increase the
likelihood of false negative diagnoses [9]. A number of studies in
both high and low endemic settings have found microscopy to
underestimate prevalence by a factor of up to three when
compared with molecular diagnosis [57,69–72]. The decreasing
cost and time implications of molecular diagnosis may mean that
these gold standard diagnostic techniques become the standard for
parasite rate surveys in the future. A global map of PCR-positive
parasitemia rates would almost certainly reveal a larger underlying
reservoir of infections and, possibly, reveal systematic differences
in patterns of endemicity than we are able to resolve currently with
less sensitive diagnostic methods.
The lower parasite loads must be interpreted in the context of
implications for progression to clinical disease. For example,
Plasmodium vivax is known to induce fevers at comparatively lower
parasite densities than P. falciparum, a feature likely linked to overall
inflammatory responses of greater magnitude [16]. P. vivax is also
comparable to P. falciparum in its potential to cause anaemia
regardless of lower parasite densities, due to a combination of
dyserythropoesis and repeated bouts of haemolysis [22]. A recent
hospital-based study at a site in eastern Indonesia of hypo- to
meso-endemic transmission of both species showed far lower
frequencies of parasitemia .6,000/uL among inpatients classified
as having not serious, serious, and fatal illness with a diagnosis of P.
vivax compared to P. falciparum [24]. Further, the majority of case
reports describing severe and fatal illness with a diagnosis of vivax
malaria typically show parasitemia .5,000/uL. In contrast, the
World Health Organization threshold for severe illness attribut-
able to hyperparasitemia with P. falciparum is .200,000/uL [73].
In brief, the relationship between prevalence and risk of disease
and transmission for P. vivax is distinct from that for P. falciparum,
and it is weighted more heavily towards substantial risks at much
lower parasite densities and levels of prevalence of microscopically
patent parasitemia.
The capacity of P. vivax hypnozoites to induce relapsing
infections has a number of important implications. First, because
dormant liver stage infections are not detectable in routine parasite
rate surveys, our maps do not capture the potentially very large
reservoir of asymptomatic infections sequestered in each popula-
tion. Evidence is emerging that this hidden reservoir may be
substantially larger than previously thought, with long-latency P.
vivax phenotypes both prevalent and geographically widespread
[37]. Whilst not contributing to clinical disease until activated,
these dormant hypnozoites ultimately play a vital role in sustaining
transmission since they are refractory to blood-stage antimalarial
chemotherapy and interventions to reduce transmission. Hypno-
zoites also ensure an ability of P. vivax to survive in climatic
conditions that cannot sustain P. falciparum transmission. Second,
the P. vivax parasite rates observed in population surveys detect
both new and relapsing infections, although the two are almost
never distinguishable. This confounds the relationship between
observed infection prevalence and measures of transmission
intensity such as force of infection or the entomological inoculation
rate. This, in turn, has implications for the use of transmission
models seeking to evaluate or optimise control options for P. vivax
[2,9,27,74]. The current unavailability of any diagnostic method
for detecting hypnozoites [75] and our resulting ignorance about
the size and geographic distribution of this reservoir therefore
remain critical knowledge gaps limiting the feasibility of regional
elimination [9]. It is also worth noting that conventional parasite
rate data do not measure multiplicity of infection which is an
additional potential confounding effect between observed infection
prevalence and transmission intensity.
P. vivax in Africa and Duffy Polymorphism
Our map of P. vivax endemicity and estimates of populations at
risk in Africa are heavily influenced by a single assumption: that
the fraction of the population estimated to be negative for the
Duffy antigen [43] is refractory to infection with P. vivax. A body of
empirical evidence is growing, however that P. vivax can infect and
cause disease in Duffy negative individuals, as reported in
Madagascar [76] and mainland sub-Saharan Africa [77–80] as
well as outside Africa [81,82]. Whether the invasion of erythro-
cytes via Duffy antigen-independent pathways is a newly evolved
mechanism, or whether this capacity has been overlooked by the
misdiagnosis of P. vivax in Africa as P. ovale remains unresolved
[9,42,59]. Whilst this accumulated evidence stands contrary to our
simplifying assumption of complete protection in Duffy negative
individuals, there is currently no evidence to suggest that such
infections are anything but rare and thus are unlikely to have any
substantive influence on the epidemiology or infection prevalence
of P. vivax at the population scale throughout most of Africa. We
also make no provision in our model for a protective effect in
Duffy-negative heterozygotes, although such protection has been
observed in some settings [83–86]. The movement and mixing
within Africa of human populations from diverse ethnographic
backgrounds complicates contemporary patterns of Duffy nega-
tivity and, in principle, could yield local populations with
substantially reduced protection from P. vivax infection in the
future. Indeed, the implications for our map of population
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movement go beyond the effect of Duffy negativity: the carriage of
parasites from high to low endemic regions, for example by
migratory workers, may play an important role in sustaining
transmission in some regions and further research is required to
investigate such processes.
Mapping to Guide Control
There exists for P. falciparum a history of control strategies linked
explicitly to defined strata of endemicity, starting with the first
Global Malaria Eradication Programme [18,87,88] and undergo-
ing a series of refinements that now feature in contemporary
control and elimination efforts. Most recently, stratification has
been supported by insights gained from mathematical models
linking endemic levels to optimum intervention suites, control
options, and timelines for elimination planning [2,89–95]. In stark
contrast, control options for P. vivax are rarely differentiated by
endemicity, and there is little consensus around how this may be
done. In part, the absence of agreed control-oriented strata of P.
vivax endemicity stems from the biological complexities and
knowledge gaps that prevent direct interpretation of infection
prevalence as a metric for guiding control. It is also to some extent
inevitable that the dogma of unstratified control becomes self-
propagating: risk maps are not created because control is not
differentiated by endemicity, but that differentiation cannot
proceed without reliable maps.
As well as providing a basis for stratified control and treatment,
the endemicity maps presented here have a number of potential
applications in combination with other related maps. First, there is
an urgent need to better identify regions where high P. vivax
endemicity is coincident with significant population prevalence of
glucose-6-phosphate dehydrogenase deficiency (G6PDd). This
inherited blood disorder plays a key role in chemotherapy policy
for P. vivax because primaquine, the only registered drug active
against the hypnozoite liver stage is contra-indicated in G6PDd
individuals in whom it can cause severe and potentially fatal
haemolytic reactions [96,97]. A new global map of G6PDd
prevalence is now available (Howes et al, submitted) which can be
combined with the endemicity maps presented here to provide a
rational basis for estimating adverse outcomes and setting appro-
priate testing and treatment protocols. Moreover, in practice most
clinical infections are managed without differentiating the causative
parasite species: combining the endemicity maps for P. vivax and P.
falciparum may therefore inform unified strategies for malaria control
programs and policy [28]. It has been proposed, for example, that
artemesinin-based combination therapy (ACT) be adopted for all
presumptively diagnosed malaria in areas coendemic for both
species, as opposed to a separate ACT/chloroquine treatment
strategy [98]. Further, in some regions more than 50% of patients
diagnosed with falciparum malaria go on to experience an attack of
vivax malaria in the absence of risk of reinfection [99]. This high
prevalence of hypnozoites may also justify presumptive therapy with
primaquine against relapse with any diagnosis of malaria where the
two species occur at relatively high frequencies. Such geographically
specific cross-parasite treatment considerations hinge on robust risk
maps for both species.
Future Challenges in P. vivax Cartography
Numerous research and operational challenges remain unad-
dressed that would provide vital insights into the geographical
distribution of P. vivax and its impacts on populations. Perhaps the
highest priority is to improve understanding of the link between
infection prevalence and clinical burden in both P. vivax mono-
endemic settings and where it is coendemic with P. falciparum.
Official estimates of national and regional disease burdens for P.
vivax remain reliant on routine case reporting of unknown fidelity
and are only crudely distinguished from P. falciparum [100]. It is
illuminating that only 53 of the 95 P. vivax endemic countries were
able to provide vivax-specific routine case reporting data, and
there is a clear mandate for strengthening the routine diagnosis
and reporting of P. vivax cases. Cartographic approaches to
estimating P. vivax burden can therefore play a crucial role in
triangulating with these estimates to provide insight into the
distribution of the disease independent of health system surveil-
lance and its attendant biases [27,101–105]. There is also a
particular need to define burden and clinical outcomes associated
with P. vivax in pregnancy [9,106] and other clinically vulnerable
groups, most notably young children. Linking infection prevalence
to clinical burden implies the need to better understand the
contribution of relapsing infections to disease. Whilst the
magnitude of this contribution is known to be highly heteroge-
neous, its geographical pattern is poorly measured and causal
factors only partially understood [39,41].
Further challenges lie in understanding how P. falciparum and P.
vivax interact within human hosts and how these interactions
manifest at population levels. Comparison of the maps for each
species reveals a complete spectrum from areas endemic for only
one parasite through to others where both species are present at
broadly equal levels. Whilst identifying these patterns of
coendemicity is an important first step, the implications in terms
of risks of coinfection and clinical outcomes, antagonistic
mechanisms leading to elevated severe disease risk, or cross-
protective mechanisms of acquired immunity remain disputed
[20,107–109].
Conclusions
To meet international targets for reduced malaria illness and
death, and to progress the cause of regional elimination, the
malaria research and control communities can no longer afford to
neglect the impact of P. vivax. Its unique biology and global
ubiquity present challenges to its elimination that greatly surpass
those of its higher-profile cousin, P. falciparum. Making serious
gains against the disease will require substantive strengthening of
the evidence base on almost every aspect of its biology,
epidemiology, control and treatment. The maps presented here
are intended to contribute to this effort. They are all made freely
available from the MAP website [110] along with regional and
individual maps for every malaria-endemic country. Users can
access individual map images or download the global surfaces for
use in a geographical information system, allowing them to
integrate this work within their own analyses or produce bespoke
data overlays and displays. We will also make available, where
permissions have been obtained, all underlying P. vivax parasite
rate surveys used in this work.
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